Long‐term outcomes of thalidomide in refractory Crohn's disease

Authors:

Abstract
Summary: Background: Several open‐label and retrospective studies have indicated that thalidomide may be beneficial in patients with refractory Crohn's disease (CD).Aim: To report our long‐term experience with the use of thalidomide for adults with refractory Crohn's disease.Methods: We conducted a retrospective study of long‐term clinical and safety outcomes among adults treated with thalidomide for refractory Crohn's disease. Response was defined as a clinician's assessment of improvement after at least 7 days treatment of one or more of the following: bowel movement frequency, fistula output, rectal bleeding, abdominal pain, extraintestinal manifestations, or well‐being. Remission required all of the following: P = 0.01). An adverse event occurred in 68% of patients. Approximately one‐third of patients (38%) experienced neuropathy.Conclusions: Thalidomide appears to be safe and effective in some patients with refractory Crohn's disease. Although side effects may limit long‐term use, thalidomide has potential to induce significant clinical responses.

This publication has 33 references indexed in Scilit: